Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02325674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MEASuRE: Metreleptin Effectiveness And Safety Registry

Study acronym: MEASuRE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Sponsor changed: Amryt Pharma to Chiesi Farmaceutici S.p.A. Site details revised at 6 of 28 sitesv12 Show 1 more changeShow less
    • Site details revised at 6 of 28 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Lead sponsor: Aegerion Pharmaceuticals, Inc. to Amryt Pharma Site details revised at 3 of 28 sitesv11 Show 1 more changeShow less
    • Site details revised at 3 of 28 sites
  3. Study sites: 27 to 28v10
  4. Study sites: 26 to 27v9
  5. Start date: Jan 15, 2016 to Oct 11, 2016 Primary endpoint revised · Study sites: 22 to 26 · Interventions: Metreleptin (Drug)v8 Show 3 more changesShow less
    • Primary endpoint revised
    • Study sites: 22 to 26
    • Interventions: Metreleptin (Drug)

    See this version in full on ClinicalTrials.gov ↗

Show 6 earlier versionsHide 6 earlier versions
  1. Primary endpoint revised Study sites: 16 to 22 · Secondary endpoints: details revised at 3 of 3 entries · Study description expanded, about 68 words · 1 morev7 Show 4 more changesShow less
    • Study sites: 16 to 22
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description expanded, about 68 words
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 15 to 16 Eligibility criteria expanded, about 2 wordsv6 Show 1 more changeShow less
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites revised (15)v5 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 12 to 15v4
  5. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Oct 2029 to Oct 31, 2031 · Study sites: 1 to 12 · Start date: Jan 2016 to Jan 15, 2016 · 3 morev3 Show 6 more changesShow less
    • Primary and study completion dates: Oct 2029 to Oct 31, 2031
    • Study sites: 1 to 12
    • Start date: Jan 2016 to Jan 15, 2016
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study title shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  6. Lead sponsor: AstraZeneca to Aegerion Pharmaceuticals, Inc. Start date: Dec 2014 to Jan 2016v2 Show 1 more changeShow less
    • Start date: Dec 2014 to Jan 2016
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Trial Details
NCT Number NCT02325674
Lead Sponsor Chiesi Farmaceutici S.p.A.
Conditions Generalised Lipodystrophy, Partial Lipodystrophy
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov